




Ever and Current Commercial Tobacco and Nicotine Product Use in the United States: PATH Study Wave 7 (2022-2023)

CRST and CAStoR collaborated to present weighted prevalence estimates from analyses of the Population Assessment of Tobacco and Health (PATH) Study, a national longitudinal study designed to be representative of the civilian noninstitutionalized US population. This brief presents results from Wave 7, which was fielded January 2022 through April 2023, and includes estimated prevalence of ever and current use of commercial tobacco products, as well as current commercial tobacco product use by demographic characteristics.

Figure 1: Ever and Current Use of Commercial Tobacco and Nicotine Products among US adults, PATH Study Wave 7 (2022-2023), N= 28,211



Notes: Ever: Regular ever established use. Current: Regular established use and used the product on 1 or more days in the past 30 days.



Table 1: Current Commercial Tobacco and Nicotine Product Use among US Adults by Age, Sex, and Race/Ethnicity, PATH Study Wave 7 (2022-2023), N=28,211*

	Cigarettes N, % (95% CI)	E-Cigarettes N, % (95% CI)	All Cigars N, % (95% CI)	Smokeless N, % (95% CI)	Nicotine Pouches N, % (95% CI)	IQOS N, % (95% CI)
Age, years						
18-24	373, 4.3 (3.8, 5.0)	1390, 15.3 (14.6, 16.1)	138, 1.4 (1.1, 1.7)	54, 0.7 (0.4, 1.0)	132, 1.5 (1.2, 1.9)	2, 0.0 (0.0, 0.3)
25-34	1115, 13.5 (12.6, 14.3)	864, 10.8 (9.7, 12.0)	284, 3.3 (2.9, 3.8)	125, 1.9 (1.4, 2.5)	119, 1.6 (1.4, 1.9)	0, 0.0
35-54	1772, 16.9 (15.3, 18.6)	488, 4.7 (4.0, 5.4)	283, 2.7 (2.4, 3.1)	222, 2.8 (2.5, 3.2)	88, 0.9 (0.6, 1.3)	3, 0.0 (0.0, 0.2)
55+	1520, 11.6 (10.9, 12.3)	159, 1.3 (1.0, 1.8)	195, 1.8 (1.5, 2.1)	145, 1.5 (1.2, 2.0)	20, 0.2 (0.1, 0.3)	1, 0.0 (0.0, 0.1)
Sex						
Female	2556, 11.5 (10.9, 12.2)	1485, 5.1 (4.9, 5.4)	294, 1.1 (0.9, 1.3)	39, 0.2 (0.1, 0.3)	65, 0.3 (0.2, 0.4)	2, 0.0 (0.0, 0.1)
Male	2224, 14.2 (13.4, 15.0)	1416, 6.4 (5.8, 7.1)	606, 3.6 (3.3, 3.9)	507, 3.8 (3.4, 4.2)	294, 1.4 (1.2, 1.6)	4, 0.0 (0.0, 0.1)
Race/Ethnicity						
Hispanic	683, 9.8 (9.0, 10.7)	549, 4.7 (4.0, 5.4)	134, 1.8 (1.3, 2.5)	26, 0.4 (0.2, 0.6)	35, 0.4 (0.2, 0.7)	0, 0.0
NH White	2906, 13.7 (12.8, 14.6)	1783, 6.4 (5.9, 6.9)	367, 1.9 (1.8, 2.0)	455, 2.7 (2.4, 3.1)	284, 1.1 (1.0, 1.3)	4, 0.0 (0.0, 0.1)
NH Black	864, 16.0 (14.7, 17.4)	267, 3.9 (3.4, 4.5)	335, 6.0 (5.3, 6.9)	26, 0.5 (0.3, 0.9)	14, 0.3 (0.1, 0.7)	2, 0.1 (0.0, 0.6)
NH Other	327, 9.4 (8.0, 11.0)	302, 5.9 (4.8, 7.2)	64, 1.8 (1.1, 3.0)	39, 1.3 (0.9, 1.9)	26, 0.6 (0.3, 1.1)	0, 0.0
Overall	4780, 12.8 (12.3, 13.4)	2901, 5.7 (5.4, 6.1)	900, 2.3 (2.2, 2.5)	546, 1.9 (1.7, 2.1)	359, 0.8 (0.7, 0.9)	6, 0.0 (0.0, 0.0)

*This table presents unweighted subgroup counts, unweighted counts of individuals using specific products within those subgroups, and weighted prevalence along with corresponding confidence intervals for various categories. Abbreviations: CI, Confidence interval; NH, Non-Hispanic



Technical Note

The PATH Wave 7 Public Use Dataset includes derived variables that indicate ever regular established use, current product use, and using a product on one of the previous 30 days, which were used for this analysis. All Cigars includes traditional or large cigars, cigarillos, and filtered cigars. Smokeless includes snuff, dip, and chew. To account for the complex sampling design, variance was estimated using Balanced Repeated Replications, applying a Fay's factor of 0.3, with the Wave 7 Adult Cross-sectional weights. Please note that the sum of subgroup estimates may not equal the overall population estimates due to rounding or the exclusion of participants who did not report age, sex, race, or ethnicity.

More information about the PATH study can be found here: <https://doi.org/10.3886/ICPSR36498>

Disclaimer: CRST is committed to rapid surveillance, including rapid dissemination, as such, the findings presented here are preliminary and subject to change.